Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Zynerba Pharmaceuticals, Inc. (ZYNE)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsDec-31-22Dec-31-21Dec-31-20Dec-31-19Dec-31-18Dec-31-17Dec-31-16Dec-31-15
   10-K10-K10-K10-K10-K10-K10-K10-K
Revenues  0.00.00.00.00.10.00.00.3
            Revenue growth     -100.0% -100.0%-97.4%-65.6%
Cost of goods sold  0.00.00.00.00.00.00.00.0
Gross profit  0.00.00.00.00.10.00.00.3
            Gross margin      100.0% 100.0%100.0%
Selling, general and administrative   [+]14.215.316.413.913.210.06.45.4
Research and development  21.121.435.720.427.222.816.87.4
Other operating expenses        0.1 
EBITDA   [+]-35.0-36.5-51.9-34.2-40.3-32.7-23.2-12.5
            EBITDA margin      -46858.4% -320434.1%-4483.7%
Depreciation and amortization  0.20.20.20.10.10.10.10.0
EBIT   [+]-35.3-36.8-52.1-34.3-40.4-32.8-23.3-12.5
            EBIT margin      -46974.2% -321472.8%-4493.1%
Non-recurring items   [+]      -0.1 
Interest income  0.80.00.21.51.00.50.10.0
Other income (expense), net   [+]-0.6-0.60.5-0.1-0.50.3-0.3 
Pre-tax income  -35.0-37.3-51.3-32.9-39.9-32.0-23.4-12.5
Income taxes  0.00.00.00.00.00.00.00.0
            Tax rate  0.0%0.0%0.0%0.0%0.0%0.0%0.1% 
Net income  -35.0-37.3-51.3-32.9-39.9-32.0-23.4-12.6
            Net margin      -46408.3% -322600.1%-4500.3%
   
Basic EPS   [+]($0.82)($0.95)($1.90)($1.50)($2.61)($2.48)($2.58)($2.82)
Diluted EPS   [+]($0.82)($0.95)($1.90)($1.50)($2.61)($2.48)($2.58)($2.82)
   
Shares outstanding (basic)   [+]42.739.327.022.015.312.99.14.5
Shares outstanding (diluted)   [+]42.739.327.022.015.312.99.14.5
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy